illumiSonics Inc. Welcomes Benjamin Ecclestone as Principal Research Scientist

September 22, 2025 - illumiSonics Inc., a leading innovator in advanced biomedical imaging technologies, is pleased to announce the appointment of Dr. Benjamin Ecclestone as Principal Research Scientist.

Dr. Ecclestone brings great expertise in biomedical imaging and has played a key role in developing the company’s core technologies of PARS® (photon absorption remote sensing) and MLI™ (Multi-Laser Imaging) both central pillars of illumiSonics’ proprietary imaging platform. His work has been instrumental in shaping the capabilities of non-contact, label-free histological imaging, contributing to more than 14 peer reviewed publications and 5 patents on PARS and MLI to date.

“We are thrilled to have Ben join our team,” said Dr, John Mackey, CEO at illumiSonics. “He’s been a major contributor to PARS and MLI from the beginning, and his experience will help drive our next phase of innovation.”

Dr. Ecclestone earned his Ph.D. in Systems Design Engineering from the University of Waterloo where he was awarded the prestigious Vanier Canada Graduate Scholarship, one of Canada’s highest academic honors for doctoral researchers. His doctoral thesis, " Label-free optical microscopy: Photon Absorption Remote Sensing (PARS) and other methods for label-free histopathological imaging of tissues", laid the foundation for much of the current progress in the PARS and MLI space.

“I’m excited to join illumiSonics and continue building technologies that will change the landscape of histopathology and tissue diagnostics,” said Dr. Ecclestone. “It’s a privilege to be part of a team that shares the vision of translating cutting-edge science into real-world impact.”

About illumiSonics Inc. illumiSonics Inc. is a Waterloo, Ontario based company that has developed the MLI™ (Multi-Laser Imaging) platform: a transformative imaging device for life science research, digital pathology, fresh tissue diagnostics and eye imaging. MLI is the most advanced optical absorption imaging device to date. It captures optical absorption from radiative contrast (e.g., autofluorescence), non-radiative relaxation (e.g., temperature, pressure) and scattering channels (indirect optical absorption measurement) simultaneously without contact with the tissue. The ability to generate multiple diagnoses from a single tissue sample and eliminate the need for staining addresses an unmet medical need that has the potential to save lives and reduce costs. For more information, visit www.illumisonics.com.